SCHEMBL684569

SCHEMBL684569

Cc1ccc(CC(=O)CN2C(=O)S/C(=C\c3ccc(-c4ccc(C(=O)O)cc4)o3)C2=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.66
TDP1 Q9NUW8 4/20 0.60
MEN1 O00255 4/20 0.60
POLB P06746 4/20 0.60
KMT2A Q03164 4/20 0.60
L3MBTL1 Q9Y468 4/20 0.60
PKM P14618 2/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
STAT3 P40763 1/20 0.59
LCK P06239 1/20 0.58
ITGB2 P05107 4/20 0.58
ITGAM P11215 4/20 0.58
KDM4E B2RXH2 2/20 0.57
MAPT P10636 2/20 0.57
APEX1 P27695 2/20 0.57
SLC1A3 P43003 3/20 0.55
PTPN22 Q9Y2R2 2/20 0.54
PSMB8 P28062 3/20 0.54
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16687571 0.89 ENPP2 (0.82) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL5146767 0.82 STAT3 (0.80) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL5146772 0.82 STAT3 (0.80) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL5144867 0.82 PTPN22 (0.75) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL46552 0.82 PTPN22 (0.75) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL4892925 0.81 STAT3 (0.75) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL4892919 0.81 STAT3 (0.75) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL17715075 0.80 ENPP2 (0.69) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL46549 0.80 ITGB2 (0.63) ENPP2TDP1MEN1POLBKMT2A
SCHEMBL684272 0.80 ENPP2 (0.83) ENPP2TDP1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010255-A1 Compounds and Methods for Regulating Integrins ATEGRIN, INC. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010255-A1 Compounds and Methods for Regulating Integrins ITGB8, ITGB3, ITGAM ENPP2 1581/4885TDP1 4431/4885MEN1 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.